Discovering targeted
medicines

Redx is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted medicines for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis

Drug discovery with a strong track record

Our core strengths in medicinal chemistry and translational science enable us to discover and develop potentially differentiated, novel compounds against biologically or clinically validated targets where there is the opportunity to create best-in-class or first-in-class treatments for diseases of unmet medical need. We have built an attractive portfolio of assets and have a strong track record of drug discovery having delivered five molecules to clinical stage development. Our focus is on advancing our differentiated ROCK portfolio which includes our lead asset, RXC007, a next-generation, selective ROCK2 inhibitor for the treatment of interstitial lung diseases and RXC008, a potential first-in-class GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease. Our oncology pipeline is led by RXC004, a Porcupine inhibitor targeting Wnt-ligand dependent tumours, in combination with anti-PD-1 therapy; and our world-class drug discovery engine is advancing a pipeline of research programmes and collaborations in both fibrotic diseases and oncology.

Our Pipeline

Target/Product

Indications

Research

Preclinical

Phase 1

Phase 2

Phase 3

Upcoming Milestones

Fibrosis

Lead: Idiopathic pulmonary fibrosis (IPF)
Potential: ILD, cancer-associated fibrosis

Phase 2a topline data – Q1 2024

Fibrostenotic Crohn’s Disease

CTA submission – end 2023

Oncology

Genetically selected MSS mCRC

Porcupine

Topline data in combination with anti-PD-1 – H2 2023

Biliary tract cancer and pancreatic cancer

Porcupine2
Discovery Engine

Fibrosis, cancer-associated fibrosis

Progress programmes – target of 2 IND’s by 2025

Research Targets
(Multiple Programmes)

Oncology & fibrosis

Partnered

Idiopathic pulmonary fibrosis (IPF)

Licensed to AstraZeneca

Oncology

Sold to Jazz Pharmaceuticals

MAPK Pathway Target

Oncology

Progress Jazz Collaboration

DDR: Discoidin Domain Receptor; RAF: Rapidly accelerated fibrosarcoma; GI: Gastrointestinal; MAPK: Mitogen-activated protein kinase; MSS mCRC: Microsatellite-Stable Metastatic Colorectal Cancer; ROCK: Rho associated protein kinase

Our Pipeline

Fibrosis
Phase 2

Lead: Idiopathic pulmonary fibrosis (IPF)
Potential: ILD, cancer-associated fibrosis

UPCOMING MILESTONES

Phase 2a topline data – Q1 2024

Preclinical

Fibrostenotic Crohn’s Disease

UPCOMING MILESTONES

CTA submission – end 2023

Oncology
Porcupine
Phase 2

Genetically selected MSS mCRC

UPCOMING MILESTONES

Topline data in combination with anti-PD-1 – H2 2023

Porcupine2
Phase 2

Biliary tract cancer and pancreatic cancer

Discovery Engine
Research

Fibrosis, cancer-associated fibrosis

UPCOMING MILESTONES

Progress programmes – target of 2 IND’s by 2025

Research Targets
(Multiple Programmes)

Research

Oncology & fibrosis

Partnered
Preclinical

Idiopathic pulmonary fibrosis (IPF)

UPCOMING MILESTONES

Licensed to AstraZeneca

UPCOMING MILESTONES

Sold to Jazz Pharmaceuticals

MAPK Pathway Target

Research

Oncology

UPCOMING MILESTONES

Progress Jazz Collaboration

DDR: Discoidin Domain Receptor; RAF: Rapidly accelerated fibrosarcoma; GI: Gastrointestinal; MAPK: Mitogen-activated protein kinase; MSS mCRC: Microsatellite-Stable Metastatic Colorectal Cancer; ROCK: Rho associated protein kinase

Our values

At Redx, our ambition is to create world leading medicines that will transform patients’ lives, by delivering better medicines faster.

Our core strengths in medicinal chemistry and translational science enable us to discover and develop potentially differentiated, novel compounds against biologically or clinically validated targets where there is the opportunity to create best-in-class or first-in-class treatments for diseases of unmet medical need.

Our five core company values that underpin everything we do: